Marta Cossu1, Romina Andracco2, Alessandro Santaniello2, Maurizio Marchini2, Adriana Severino2, Monica Caronni2, Timothy Radstake1, Lorenzo Beretta3. 1. Department of Rheumatology, Clinical Immunology and Laboratory of Translational Immunology, University Medical Center, Utrecht, Netherlands and. 2. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Referral Center for Systemic Autoimmune Diseases, Milano, Italy. 3. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Referral Center for Systemic Autoimmune Diseases, Milano, Italy lorberimm@hotmail.com.
Abstract
OBJECTIVE: To improve knowledge of vasculopathy in SSc through the assessment of serum levels of circulating angiogenetic and endothelial dysfunction markers in patients at different stages of the disease. METHODS: Sera from 224 subjects were obtained and concentrations of angiopoietin-2, chemokine (C-X-C motif) ligand (CXCL)-16 (CXCL16), E-selectin, soluble intercellular adhesion molecule-1, IL-8 (CXCL8), soluble vascular adhesion molecule-1 and VEGF were determined by a Luminex assay. Subjects included 43 healthy controls, 47 early SSc patients according to LeRoy and Medsger without other signs and symptoms of evolutive disease, 48 definitive SSc (defSSc) patients according to the 2013 ACR/EULAR criteria without skin or lung fibrosis, 51 lcSSc subjects and 35 dcSSc subjects. RESULTS: The four groups of patients showed well-distinct clinical and laboratory characteristics, with a linear decreasing trend in forced vital capacity and diffusing capacity for carbon monoxide % predicted values from early SSc to defSSc to lcSSc and to dcSSc, and a linear increasing trend in ESR, and in the prevalence of abnormal CRP, serum gamma globulins and lung fibrosis (all P < 0.0001). Highly significant linear trends pointing to an increase in angiopoietin-2 (P < 0.0001), CXCL16 (P < 0.0001), E-selectin (P = 0.001) and soluble intercellular adhesion molecule-1 (P = 0.002) in relation to the different disease subsets were observed. CONCLUSION: Markers characterizing vascular activation are found to be increased in SSc patients from the earliest stages of disease when clinical and laboratory findings of advanced disease cannot yet be detected. These abnormalities progress with the appraisal of the first sclerodermatous manifestation in defSSc and further increase with the onset of fibrotic manifestations.
OBJECTIVE: To improve knowledge of vasculopathy in SSc through the assessment of serum levels of circulating angiogenetic and endothelial dysfunction markers in patients at different stages of the disease. METHODS: Sera from 224 subjects were obtained and concentrations of angiopoietin-2, chemokine (C-X-C motif) ligand (CXCL)-16 (CXCL16), E-selectin, soluble intercellular adhesion molecule-1, IL-8 (CXCL8), soluble vascular adhesion molecule-1 and VEGF were determined by a Luminex assay. Subjects included 43 healthy controls, 47 early SSc patients according to LeRoy and Medsger without other signs and symptoms of evolutive disease, 48 definitive SSc (defSSc) patients according to the 2013 ACR/EULAR criteria without skin or lung fibrosis, 51 lcSSc subjects and 35 dcSSc subjects. RESULTS: The four groups of patients showed well-distinct clinical and laboratory characteristics, with a linear decreasing trend in forced vital capacity and diffusing capacity for carbon monoxide % predicted values from early SSc to defSSc to lcSSc and to dcSSc, and a linear increasing trend in ESR, and in the prevalence of abnormal CRP, serum gamma globulins and lung fibrosis (all P < 0.0001). Highly significant linear trends pointing to an increase in angiopoietin-2 (P < 0.0001), CXCL16 (P < 0.0001), E-selectin (P = 0.001) and soluble intercellular adhesion molecule-1 (P = 0.002) in relation to the different disease subsets were observed. CONCLUSION: Markers characterizing vascular activation are found to be increased in SSc patients from the earliest stages of disease when clinical and laboratory findings of advanced disease cannot yet be detected. These abnormalities progress with the appraisal of the first sclerodermatous manifestation in defSSc and further increase with the onset of fibrotic manifestations.
Authors: Chiara Bellocchi; Jun Ying; Ellen A Goldmuntz; Lynette Keyes-Elstein; John Varga; Monique E Hinchcliff; Marka A Lyons; Peter McSweeney; Daniel E Furst; Richard Nash; Leslie J Crofford; Beverly Welch; Jonathan G Goldin; Ashley Pinckney; Maureen D Mayes; Keith M Sullivan; Shervin Assassi Journal: Arthritis Rheumatol Date: 2021-02-28 Impact factor: 10.995
Authors: Marta Cossu; Lorenzo Beretta; Petra Mosterman; Maria J H de Hair; Timothy R D J Radstake Journal: Clin Rev Allergy Immunol Date: 2018-12 Impact factor: 8.667
Authors: Marta Colletti; Angela Galardi; Maria De Santis; Giacomo Maria Guidelli; Angela Di Giannatale; Luigi Di Luigi; Cristina Antinozzi Journal: Int J Mol Sci Date: 2019-09-04 Impact factor: 5.923
Authors: Maynara Santana-Gonçalves; Djúlio Zanin-Silva; Álvaro Henrique-Neto; Daniela A Moraes; Marianna Y Kawashima-Vasconcelos; João R Lima-Júnior; Juliana B E Dias; Vinícius Bragagnollo; Júlia T C de Azevedo; Dimas T Covas; Kelen C R Malmegrim; Leandra Ramalho; Maria Carolina Oliveira Journal: Ther Adv Musculoskelet Dis Date: 2022-03-28 Impact factor: 5.346
Authors: Aleksey Mitev; Lisa Christ; Daria Feldmann; Moritz Binder; Kim Möller; Anna-Maria Kanne; Thomas Hügle; Peter M Villiger; Reinhard E Voll; Stephanie Finzel; Florian Kollert Journal: Arthritis Res Ther Date: 2019-12-02 Impact factor: 5.156